Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, CXP

New England Biolabs® opens subsidiary in the Republic of Korea


IPSWICH, Mass., April 3, 2024 /PRNewswire/ -- New England Biolabs (NEB®), a world leader in the production of reagents for the life science industry, extended its global subsidiary network with the opening of New England Biolabs Korea Ltd. (NEB Korea).

The Republic of Korea is emerging as a global leader in the life science space, as a result of strong public sector support and private sector investments. NEB has supported researchers in South Korea for many years through its distribution network. NEB Korea will now bring a higher level of service to our valued customers and local distributors in this important market.

"This new subsidiary office will provide the scientific research community in South Korea with more efficient access to the latest NEB products and technical support in the local time zone, as well as custom partnership opportunities," says Elin Yoon, Country Manager for NEB Korea. "We are excited to bring this level of support to our customers, and to help accelerate their research."

"It's been encouraging to see the rapid growth of South Korea's life science industry over the past few years, which is a testament to the country's relentless focus on laying the groundwork for new technologies and advancements," stated Carole Keating, Executive Director of International Business at NEB. "The expansion of our subsidiary network enables NEB to offer even greater personalized service to our customers, rapid delivery, and the ability to explore higher levels of collaboration."

NEB also maintains subsidiary offices in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore and the United Kingdom.

For more information, visit www.neb.com, e-mail [email protected]  or call +82-31-738-1128.

About New England Biolabs 
Established in the mid 1970's, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the UK. For more information about New England Biolabs visit www.neb.com.

NEB®, NEW ENGLAND BIOLABS®, and NEB® are registered trademarks of New England Biolabs, Inc.

SOURCE New England Biolabs, Inc.


These press releases may also interest you

at 21:29
HIX.AI, an all-in-one AI writing copilot has officially launched HIX Tutor, a powerful AI homework helper that provides step-by-step solutions to homework problems and exam questions. The homework AI tool is designed to help with all subjects...

at 21:25
A news report from China.org.cn on why did the Chinese accept scientific socialism? The Chinese always have dreamed to make their country a Utopia. In the Confucian classic The Book of Rites, we read, "When the Great Way prevails, the world belongs...

at 21:21
CheolSun Kang corrects his previous early warning announcement of March 14, 2024 to advise he never had ownership or control over Graphizer Inc., as previously set out in the initial announcement, which holds 4,500,000 shares of AGEDB Technology Ltd....

at 21:12
Record Operating Revenues and Net Income: DeFi Technologies recorded its strongest quarter ever, achieving Operating Revenues of C$13.4 million and Operating Net Income of C$5.3 million for Q1 2024.Strategic Advancements and Product Launches: The...

at 21:11
The Honourable Harjit Sajjan, President of the King's Privy Council for Canada, Minister of Emergency Preparedness and Minister responsible for the Pacific Economic Development Agency of Canada, and the Honourable Dan Vandal, Minister of Northern...

at 21:03
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...



News published on and distributed by: